Krishna Doshi
@Krishnahdoshi
Hospice and Palliative Medicine Fellow @UTHSA| No medical advice
Excited to share that our workshop "Intern Preparedness for Residency", developed in collaboration with an incredible group of residents @MacNealIMRP, has been accepted as a poster presentation at @TheNRMP Transition to Residency Conference! 📍 Washington, DC 📅 October 11-12
Excited for applying to Heme/Onc fellowship this match season #match2026. Grateful for all the peers and mentors who’ve uplifted and guided me. Couldn’t be here without all your support! Looking forward to this year! AAMC ID: 14233494 @hemeoncfellow
Over the next 2 weeks hope to do some quick #video summaries of our #Top10Tips paper for #hpm on #survonc. Hope you enjoy! #pallonc #supponc This is Tip 1⃣ cross team collab 🤝 @GreggWeltyMD @DrN_CancerPCP @DrNicolasHart @doc_martin19 @BillyRosaPhD @OncoAlert🚨 @PallOncCoP…
Humbled to share my (very first) primary authored paper: Top 10 Tips for #hpm about #survonc Deeply grateful for my writing mentor @GreggWeltyMD senior author @DrN_CancerPCP wisdom of @DrNicolasHart and colleagues, mentees and friends @doc_martin19 with editorial insight of…
SPEAKER ANNOUNCEMENT!📣 Register today for the 2026 ASCL Conference in San Antonio, Texas and hear from @DrSukeshiArora. Find more information at latinocancer.com! #ASCL206 #LatinoCancer2026
Excited to present our abstract for a poster presentation @Myeloma_Society’s Annual meeting this fall!
Amazing insight!!! Loved listening to this.
Truly a #legacy podcast for me as this was the last conversation I had with my dear #mentor and #hpm friend the late Dr John Mulder. Grateful he let me share my heart for #pallonc #supponc and #survonc. More poignant it comes on the heels of our #paper 🍎:…
Happy to share that our abstract publication is finally out! Check it out here- meetings.asco.org/abstracts-pres… #ASCO25
Thanks to @SuzanneColeMD of @UTSouthwestern for interviewing with me for @oncodaily’s podcast - #EMPOWERINGONCOLOGISTS ✅Great insights as to how you established a research infrastructure in a community setting. ✅how you navigated through life making choices that were not the…
The first controlled trial of hydroxyurea in hemoglobin #SickleCell disease shows reductions in vaso-occlusive episodes and hospitalizations, though safety non-inferiority wasn’t met. 🔗ow.ly/RBRO50VHqxN #Hematology
ABSTRACT SUBMISSIONS DUE AUG. 1! Share your groundbreaking research on liver cancer epidemiology, survivorship and prevention at the San Antonio Liver Cancer Symposium. Submit your abstract today. We look forward to seeing you on October 10! bit.ly/4jJhkFP
So excited for this!!!
Sukeshi Arora, MD, (@DrSukeshiArora) and Danielle Fritze, MD, invite you to attend the 2025 San Antonio Liver Cancer Symposium at the Westin-San Antonio North on Oct. 9-10. Register today: mayscc.eventsair.com/2025-salcs
Nice slide for timeline of all advances in metastatic Gastric cancer till date. @ASCO #GI25 @larvol @OncoAlert
We need to bring biomarker testing in GI cancer up to the same standard we apply in breast cancer (where patients themselves are savvy enough to know & self-sort by receptor status) Excellent summary of contemporary testing of gastric cancer #gi25
The most quoted paper in Cancer is now published: Cancer Statistics, 2025 acsjournals.onlinelibrary.wiley.com/doi/full/10.33…
Dato-DXd is now approved for treating patients with HR+/HER2- MBC after prior ET and chemo. In #TB01, Dato-DXd improved PFS over chemo in this population (6.9 vs 4.9 mo, HR 0.63, p<0.001). How do you plan to use Dato-DXd for HR+/HER2- MBC, assuming immediate availability?
Datopotamab deruxtecan now @FDAOncology approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC - ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato) - ⬆️ PFS 6.9mos vs 4.5 mos - Better AE + QoL DatoDXd - AEs: Fatigue, infusion reactions, stomatitis #bcsm #OncTwitter
A new Trop2 ADC is about to become available for patients with HR+/HER2- MBC. In #TB01, datopotamab deruxtecan (Dato-DXd) improved PFS over chemotherapy, with a trend towards improved overall survival. All grade ILD rates seen in the trial were low. #bcsm astrazeneca.com/media-centre/p…
The ICU is not where patients should discover that their cancer-directed therapy is palliative in intent.
XLSA breakthrough: gene therapy potential ow.ly/uhq250UyVgN #genetherapy
Most patients don't realize their doctors and nurses think about them in the spaces between visits. While walking to the parking lot, driving home, brushing teeth… even before falling asleep. Our work is a part of us, and we really care about you. That's all.